Yüklüyor......
Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 mo...
Kaydedildi:
| Yayımlandı: | Asian J Androl |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications & Media Pvt Ltd
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6413545/ https://ncbi.nlm.nih.gov/pubmed/30460933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/aja.aja_88_18 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|